Monural Pediatric (Fosfomycin Trometamol)

Fosfomycin trometamol works by inhibiting the MurA enzyme, which is essential for the first step of bacterial cell‑wall synthesis. By blocking this pathway, the drug prevents the formation of a functional peptidoglycan layer, leading to bacterial cell death and eradication of the infection.

The dose of Monural Pediatric is determined by the prescribing clinician based on the child’s age, weight, renal function, and severity of infection. Healthcare professionals follow local guidelines and product labeling to select the appropriate regimen.

Safety of fosfomycin trometamol in pregnancy and lactation has not been fully established. It should only be used if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Monural Pediatric, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Fosfomycin trometamol offers a single‑dose oral regimen with activity against many multidrug‑resistant uropathogens, which can be advantageous over longer‑course agents such as trimethoprim‑sulfamethoxazole or nitrofurantoin. However, choice of therapy depends on local resistance patterns, patient factors and clinical guidelines.

Monural Pediatric should be stored below 25 °C, in its original packaging, and protected from moisture. Keep the product away from direct sunlight and out of reach of children to maintain its stability and potency.

Monural Pediatric is administered orally, typically as a single dose taken with a full glass of water. The exact administration instructions, including any need for food or fluid intake, are provided by the prescribing clinician.

Serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, toxic epidermal necrolysis, and Clostridioides difficile‑associated colitis. Patients should be monitored for signs of rash, fever, gastrointestinal distress, or any sudden changes in health and seek immediate medical attention if they occur.

Monural Pediatric should not be used by individuals with known hypersensitivity to fosfomycin, its salts, or any component of the formulation. Caution is also advised in patients with severe renal impairment, hepatic disease, or those taking interacting medications without appropriate monitoring.